Jiangsu Aidea Pharmaceutical Co.,Ltd.

The company was founded in 2009 and listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange in 2020. The company takes anti-AIDS drugs as its core development field, and at the same time leverages its competitive advantage in the field of human protein, and actively explores, develops and sells innovative drugs guided by unmet domestic clinical diagnosis and treatment needs. The company's main business focuses on the fields of anti-HIV and human protein. The company's main products include products in the field of anti-HIV, pharmaceuticals in the field of human protein, and products in the field of anti-cancer. Corporate honors: It won the title of “2019-2020 Yangzhou Civilized Unit”, the crude product of human urinary kinin peptide enzyme was certified as a high-tech product in Jiangsu Province in 2014, and the first-class anti-AIDS drug ACC007 was included in the “Major New Drug Creation” science and technology project of the 13th Five-Year Plan.